Effect of Intraarticular Ozone, Prolotherapy or Dexmedetomidine in Pain Limitation in Knee Osteoarthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

60 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-01

Study Completion Date

2023-10-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study aimed to compare intraarticular ozone injection, prolotherapy, or dexmedetomidine effectiveness in knee osteoarthritis patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intra Articular Injection of Ozone With Corticosteroids vs PRGF in Knee Osteoarthritis

NCT05837494

Intra Articular Injection Corticosteroids Plasma Rich in Growth Factors +1 more

COMPLETED NA

Effects of Dextrose Prolotherapy in Patients With Knee Osteoarthritis

NCT06063356

Knee Osteoarthritis

ACTIVE_NOT_RECRUITING NA

Effect of Prolotherapy in Knee Osteoarthritis.

NCT04178304

Knee Osteoarthritis

COMPLETED NA

The Effect of Dextrose Prolotherapy on Isokinetic Power in the Treatment of Knee Osteoarthritis

NCT04958213

Knee Osteoarthritis Dextrose Prolotherapy Injection Physical Therapy

COMPLETED PHASE4

Intraarticular Ozone Therapy for Pain Control in Osteoarthritis of the Knee

NCT00832312

Osteoarthritis of the Knee

TERMINATED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Osteoarthritis (OA) is a heterogeneous group of disorders of different etiologies with similar biological, morphological, and clinical manifestations and outcomes. The intraarticular injection has been recommended to alleviate the pain in the knee joint.

Ozone therapy has long been used in the management of OA. Furthermore, it has been shown to not cause a significant inflammation process or cartilage degradation. Prolotherapy is a procedure where a natural irritant is injected into the soft tissue of an injured joint. Dexmedetomidine is a selective α2-adrenergic agonist with considerable sedative and analgesic actions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Intraarticular Ozone Prolotherapy Dexmedetomidine Pain Knee Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ozone group

Patients received intraarticular ozone injection.

Group Type EXPERIMENTAL

Ozone

Intervention Type DRUG

Patients received intraarticular ozone injection.

Dextrose prolotherapy group

Patients received intraarticular dextrose prolotherapy injection.

Group Type EXPERIMENTAL

Dextrose prolotherapy

Intervention Type DRUG

Patients received intraarticular dextrose prolotherapy injection.

Dexmedetomidine group

Patients received intraarticular dexmedetomidine injection.

Group Type EXPERIMENTAL

Dexmedetomidine

Intervention Type DRUG

Patients received intraarticular dexmedetomidine injection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ozone

Patients received intraarticular ozone injection.

Intervention Type DRUG

Dextrose prolotherapy

Patients received intraarticular dextrose prolotherapy injection.

Intervention Type DRUG

Dexmedetomidine

Patients received intraarticular dexmedetomidine injection.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 30 to 65 years.
* Both genders.
* Patients diagnosed with stage 1-3 osteoarthritis according to the Kellgren-Lawrence Classification System (K-L).

Exclusion Criteria

* Patient refusal.
* History of knee trauma within the past month.
* Rheumatic disease.
* Pregnancy.
* Any surgical intervention of the knee.
* Severe cardiovascular disease.
* Morbid obese patients (body mass index (BMI) of \>35 kg/m2).
* Local infection at the site of injection.
* Bleeding diathesis.

Minimum Eligible Age

30 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No